Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.37, read 2026-11-03
Ethical does not pass the values gate
Price48.52 USD
Fair value45.93
Ethical score30.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-04Read Accumulation51.99-6.7% to today Markdown gives way to Accumulation
2026-10-26Read Markdown54.10-10.3% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-20Read Accumulation54.10-10.3% to today Markdown gives way to Accumulation after a 6% rise in 4 weeks
2026-09-24Read Markdown51.21-5.3% to today ✓Accumulation gives way to Markdown after a 14% slide in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Arxis Inc holds its Markup at $48.52. The statistical read favours the buyers, held for 4 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 4 days
Price at the screen
$48.52
Valuation
282.33 trailing · 37.83 forward price to earnings
Values screen
FAIL· score 30.0
The Workings
Five Screens, Shown in Full
Does not pass. Excluded industry: Aerospace & Defense
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Excluded industry: Aerospace & Defense
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Arxis does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ARXS's ethical verdict changes
Today ARXS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $45.93 fair value estimate, narrow competitive moat, 25.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 5.6% above the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +34% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $45.93, with a range of $45.93 to $52.82, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Defence parts maker fails ethical screen outright
Picture a supplier whose components sit inside jets and guidance systems that must work every time. Arxis makes those electronic and mechanical parts, yet the business lands straight on the excluded list for aerospace and defence work. That single ethical failure ends any interest before the numbers even matter.
Valuation adds a second clear reason to pass. Shares trade at 45 times forward earnings against a narrow moat and just 6 percent profit margins, while our fair value sits 14 percent below the current price. Revenue growth of 21 percent looks respectable, but it does not offset the premium or the ethical block.
Analyst targets sit higher still, yet the ethical screen exists precisely to keep portfolios away from this category regardless of momentum or consensus. The combination leaves no opportunity rating here.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ARXS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. The street (10 analysts) rates it none, with a mean price target of $52.
2026-10-28Markdown$54.10+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading neutral. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$54.10+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading neutral. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown · changed$54.10+0.0%Entry 11
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading neutral. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$54.10+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$54.10+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$54.10+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$54.10+0.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$54.10+0.0%Entry 6
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. The street (10 analysts) rates it none, with a mean price target of $52.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.